BioNJ Advocacy Alert Good New Jersey News Edition

Dear Members of the New Jersey Biotechnology Community: At BioNJ, we are always excited to share Good New Jersey News and this latest round helps make the case that New Jersey remains a hub for the biotechnology industry, and that our State's leadership in the life sciences is still apparent. In addition to the Good New Jersey News report from last week, in which the Battelle Technology Partner Practice Report found that the New Jersey biopharmaceutical industry in 2011 ranked second only behind California in terms of employment and economic output (Click Here to read our previous email), we have four other items to point out.

Five of the top ten biotech companies are in New Jersey. Bausch & Lomb will move its headquarters to New Jersey. The Trenton-Princeton region is one of the ten best areas for STEM graduates. Venture capital investing increased in the second quarter of 2013.

We encourage you, the dedicated members of New Jersey's biotechnology community, to spread the news even further on Twitter, Facebook, LinkedIn and your other social networking connections. That's what we will also be doing with these uplifting items. And please, please, send us information that you think your colleagues would appreciate and find useful. Enjoy and let's all spread the Good New Jersey News. Yours in BioNJ, Debbie Hart President and CEO

1. A quick analysis of the Top 25 Biotech Companies of 2013 published byGenetic Engineering & Biotechnology News reveals that five of the top ten companies have their headquarters or operations in New Jersey. The companies include: Novo Nordisk, Celgene, Teva Pharmaceutical Industries, Merck KGaA and Regeneron. The ranking of the top 25 biotechnology companies is based on their market capitalization for the latest quarter that the companies furnished figures on their numbers of outstanding shares. Click Here to read the article. 2. The Star-Ledger reported today that Valeant Pharmaceuticals said it will move the headquarters of Bausch & Lomb from Rochester, NY to a New Jersey location somewhere between Baush & Lomb's current facility in Madison and the Bridgewater Township building where Valeant maintains its U.S. base. Click Here to read the Star-Ledger article. 3. New Jersey's highly educated workforce is one of its strengths. An article published in Entrepreneur which reported that the greater Trenton-Princeton region is one of the ten best locations in the country for entrepreneurs who are looking to find areas with a high number of Science, Technology, Engineering, and Mathematics (STEM) graduates. The report stated: "The Princeton area, which is adjacent to Trenton, is home to a high concentration of biotech and pharmaceutical companies. What's more, the local Center for Excellence in STEM Education in the Trenton-Ewing metro area is working to innovate teaching techniques from prekindergarten through college. Also, the cost of living in Trenton is comparatively low, a definite plus for recent college grads carrying heavy student loan loads." Click Here to read the report.

4. A recent MoneyTree Report noted an increase in venture capital investing in the second quarter of
2013. - The Internet-Specific and Biotechnology sectors both saw increases in both dollars and number of deals in the second quarter. Additionally, companies receiving VC funding for the first time, as well as those companies in the early stage of development, experienced jumps in dollars invested in Q2 2013. - The Biotechnology industry was the second largest sector for dollars invested with $1.3 billion going into 103 deals, rising 41 percent in dollars and 4 percent in deals from the prior quarter. This increase was driven by the strength of two large funding rounds in the quarter. Medical Device investing of $543 million into 71 deals represented a 1 percent decline in both dollars and deals. Investments in the Life Sciences sector overall (Biotechnology and Medical Devices) rose 25 percent in dollars and 2 percent in deals, purely on the strength of investing in the Biotech sector. - The Life Sciences sector experienced a dramatic increase of first-time investments in the second quarter, more than doubling in dollars from the prior quarter to $328 million. There were 33 Life Sciences companies receiving venture capital funding for the first time in Q2 2013, up from only 22 companies in the first quarter. Click Here to read the MoneyTree Report press release.